Figure 2.
(A) A scatter plot showing total plasma neurofilament heavy chain protein (NfH) levels at different time points for 74 patients with amyotrophic lateral sclerosis (ALS) in a 15-month follow-up period from baseline. Median and IQRs are shown beside the total plasma NfH levels. (B) Left panel: longitudinal profiles of mean total plasma NfH levels are shown in red for ALS-Fast, in green for ALS-Intermediate and in blue for ALS-Slow in a 15-month follow-up period. Each sampling time point is reported as the time from baseline, together with the n number of samples from ALS-Fast, ALS-Intermediate and ALS-Slow subgroups. Error bars: ±SEM. Right panel: distinct curves representing cumulative survivals in the total follow-up period for ALS-Fast (red lines), ALS-Intermediate (green lines) and ALS-Slow (blue lines) subgroups. (C) Trajectories of total NfH levels in the follow-up period for individual with ALS (dashed lines) and predicted average trajectories (solid lines) are shown for ALS-Fast (red), ALS-Intermediate (green) and ALS-Slow (blue) patients. ALS-Fast: overall progression rate >1.0; ALS-Intermediate: overall progression rate 0.5–1.0; and ALS-Slow: overall progression rate <0.5.